Cytokinetics Inc vs Robinhood Markets, Inc. — how do they compare? Cytokinetics Inc trades at $76.58 (market cap $10.63B), while Robinhood Markets, Inc. trades at $94.22 (market cap $84.86B). The key difference: Robinhood Markets, Inc. is far larger — about 8× Cytokinetics Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals.
| CYTK | HOOD | |
|---|---|---|
Market Cap | $10.63B | $84.86B |
Sector | Technology | Technology |
52-Week High | $87.26 | $152.46 |
52-Week Low | $34.31 | $65.16 |
Enterprise Value | $10.74B | $91.40B |
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Robinhood (HOOD) trades at $94.52, up 1.32% in 24 hours, with a bearish technical signal from moving averages and RSI near overbought levels. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.62 actual vs. $0.44 expected, and revenue growth of 32% year-over-year. Recent news highlights expansion into UK crypto services and product diversification, though technical indicators suggest caution amid high valuation multiples.
Outlook: Bullish fundamentals with robust revenue growth and profit margins, but elevated P/E of 41.76 poses valuation risk. Opportunities include international expansion and non-crypto revenue streams; risks involve competitive pressures and reliance on market volatility. Analyst consensus price target of $123.46 implies significant upside if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →